Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research[3][4].
Reconstitute: Add 3.0 mL bacteriostatic water per 10 mg vial → ~3.33 mg/mL concentration.
Standard daily dose:2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); reconstituted: refrigerate and use within 7 days with bacteriostatic water.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard FDA-Approved Protocol (3.0 mL = ~3.33 mg/mL)
Week
Daily Dose (mg / mcg)
Units (per injection) (mL)
Week 1
1 mg / 1000 mcg
30 units (0.30 mL)
Weeks 2–12+
2 mg / 2000 mcg
60 units (0.60 mL)
Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use within 7 days when reconstituted with bacteriostatic water[1].
Supplies Needed
Plan based on an 8–16 week daily protocol at the standard 2 mg dose (after Week 1 titration).
Peptide Vials (Tesamorelin, 10 mg each):
8 weeks ≈ 11 vials (105 mg total)
12 weeks ≈ 17 vials (161 mg total)
16 weeks ≈ 22 vials (217 mg total)
Insulin Syringes (U-100, 1 mL capacity):
Per week: 7 syringes (1/day)
8 weeks: 56 syringes
12 weeks: 84 syringes
16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles):Use 3.0 mL per vial for reconstitution.
8 weeks (11 vials): 33 mL → 4 × 10 mL bottles
12 weeks (17 vials): 51 mL → 6 × 10 mL bottles
16 weeks (22 vials): 66 mL → 7 × 10 mL bottles
Alcohol Swabs:One for the vial stopper + one for the injection site each day.
Proper storage preserves peptide quality and efficacy.
Lyophilized: Store at 2–8 °C (35.6–46.4 °F); newer formulations (Egrifta SV) stable at 20–25 °C (68–77 °F) before reconstitution[1].
Reconstituted (with bacteriostatic water): Refrigerate at 2–8 °C (35.6–46.4 °F); use within 7 days[1].
Reconstituted (with sterile water): Use immediately; discard any unused portion[1].
Do not freeze reconstituted solution; avoid repeated freeze-thaw cycles.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container[10].
Rotate injection sites (abdomen at least 2 inches from navel, thighs, upper arms) to reduce local irritation[6][10].
Inject slowly; wait a few seconds before withdrawing the needle.
Monitor IGF-1 levels periodically due to potent GH stimulation; observe blood glucose in diabetic patients[9].
Document daily dose and site rotation to maintain consistency.
How This Works
Tesamorelin mimics natural human GHRH by binding to pituitary GHRH receptors, triggering pulsatile growth hormone secretion and consequent IGF-1 elevation[2]. This cascade promotes lipolysis (fat breakdown), protein synthesis, and favorable metabolic shifts. In HIV-associated lipodystrophy, daily tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles over 6–12 months[3][4]. Research also explores tesamorelin’s potential to reduce liver fat in NAFLD patients and enhance cognitive function in older adults by restoring age-related GH/IGF-1 declines[4].
Potential Benefits & Side Effects
Observations from clinical trials and FDA-approved use.
Potential Benefits:
Significant reduction in visceral adipose tissue (measurable after 3–6 months)[3].
Improved lipid profiles and potential liver fat reduction in NAFLD[4].
Enhanced cognitive function in older adults (research ongoing)[4].
Well-tolerated with maintained benefits during continuous use up to 52 weeks[3].
Common Side Effects:
Injection-site reactions: Mild redness, itching, pain, or bruising at injection area[9].
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Tesamorelin is a prescription medication (FDA-approved as Egrifta®) for HIV-related lipodystrophy. Any off-label use should comply with applicable laws and be conducted under appropriate medical supervision. Consult a qualified medical professional before considering any therapeutic use of tesamorelin.
References
Tesamorelin – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
— National Institutes of Health, NIDDK (2018)
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials
— J. Clin. Endocrinol. Metab. (2010)
